Approval of Travere Therapeutics’ NDA for Filspari was posted to the agency’s website. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TVTX:
- Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
- Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Piper Sandler health/pharma analysts to hold analyst/industry conference call